Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded a grant of $19.7m to Immatics Biotechnologies for the development of personalized adoptive cellular immunotherapies against novel and proprietary targets discovered by Immatics. This funding will support innovative projects  to be developed by a US-based subsidiary of Immatics Biotechnologies GmbH in Houston, Texas. The work will be conducted in close collaboration with MD Anderson Cancer Center (Houston), the world’s largest cancer center. Immaticswill provide more detail on its US plans and development programs in cellular immunotherapies in the near future.

Link to announcement on website CPRIT

Link to announcement on website MD Anderson Cancer Center

Media contact: Please approach us at media[at] or call +49 (7071) 5397-0.

Press Contact

Anja Heuer

Corporate Communications,
Immatics Biotechnologies GmbH

+49 89 540 415 606

Go back

We use cookies to ensure that we give you the best experience on our website.